Outstanding Benefits for Patients
DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES
- Tumors have latent vulnerabilities that can be identified through ETA.
- Agnostic to stage, grade, anatomy or morphology.
- Integrational multi-analyte interrogation of tumor interactome and tumor function.
- Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.
DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES
- Tumors have latent vulnerabilities that can be identified through ETA.
- Agnostic to stage, grade, anatomy or morphology.
- Integrational multi-analyte interrogation of tumor interactome and tumor function.
- Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.
Outstanding Benefits for Patients
Who will Benefit
✓First-line therapy has failed.
✓Risk of therapy failure is high.
✓Cancer has relapsed.
✓For newly diagnosed patients to explore best therapy options.
✓Cancer is high-grade / metastatic.
Clinically Validated (Publications)
The validation data for Exacta / The resilient protocol has been extensively published in leading peer reviewed journals.
The RESILIENT Protocol
Why Exacta
Exacta® is an intensive and in depth tumor gene expression analysis. It analyses 100s of millions of data points at the molecular level to reveal all possible targets for precision drugs. Exacta® is one of the most powerful tumor investigation and is an extreme analytical tool that reveals the driven mutations and pathways driving a personʼs cancer. Exacta is best molecular analysis for difficult cancers.
Features
✓Determines deepest genetic facets of an individual patientʼs cancer.
✓Accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome.
✓Reaches the depths of cancerʼs mechanism through 100ʼs of millions of data points.
✓Reveals mutations and pathways that are propelling a particular cancer in an individual.
✓Enables a highly sophisticated treatment strategy beyond conventional perspective.
CONTACT US